A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 7, 1997, Pages 419-430

  Despotis, G J ^a   Levine, V ^a   Joiner Maier, D ^b   Joist, J H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated clotting time; Cardiac surgery; Coagulation; Monitoring; Whole blood heparin concentration

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; KAOLIN; PROTAMINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD LEVEL; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; HEART SURGERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0030657588     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199710000-00007     Document Type: Article

References (73)

1. Hirsh J. Heparin [review]. N Engl J Med 1991; 324: 1565-1574.
2. Hill JD, Dontigny L, De Leval M, Mielke CH Jr. A simple method of heparin management during prolonged extracorporeal circulation. Ann Thorac Surg 1974; 17: 129-134.
3. Verska JJ. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg 1977; 24: 170-173.
4. Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 1977; 73: 780-782.
5. Guffin AV, Dunbar RW, Kaplan JA, Bland JW Jr. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg 1976; 55: 110-113.
6. Culliford AT, Gitel SN, Starr N, Thomas ST, Baumann FG, Wessler S, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193: 105-111.
7. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-1082.
8. Umlas J, Gauvin G, Taff R. Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay. Ann Thorac Surg 1984; 37: 301-303.
9. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990; 49: 440-444.
10. Jobes DR, Schwartz AJ, Ellison N, Andrews R, Ruffini RA, Ruffini JJ. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981; 31: 161-166.
11. Gravlee GP. Anticoagulation for cardiopulmonary bypass. In: Gravlee GD, Utley RF, eds. Cardiopulmonary Bypass: Principles and Practice. Baltimore: Williams & Wilkens, 1993; 340-380.
12. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978; 26: 231-240.
13. Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80: 520-526.
14. Mitchell GA, Garguilo RJ, Huseby RM, Lawson DE, Pochron SP, Sehuanes JA. Assay for plasma heparin using a synthetic peptide substrate for thrombin: introduction of the fluorophore aminoisophthalic acid, dimethyl ester. Thromb Res 1978; 13: 47-52.
15. Umlas J, Taff RH, Gauvin G, Swierk P. Anticoagulant monitoring and neutralization during open heart surgery - a rapid method for measuring heparin and calculating safe reduced protamine doses. Anesth Analg 1983; 62: 1095-1099.
16. Harloff M, Taraskicwicz, Fotouhi C. Comparison study of the hepcon system four and the hemostasis management system. Perfusion 1991; 6: 297-301.
17. Anido G, Freeman DJ. Heparin assay and protamine titration. Am J Clin Pathol 1981; 76: 410-415.
18. Hughes DR, Faust RJ, Didsheim P, Tinker JH. Heparin monitoring during cardiopulmonary bypass in man: use of fluorogenic heparin assay to validate activated clotting time. Anesth Analg 1982; 61: 189-190 (Abstract).
19. Despotis GJ, Joist JH, Joiner-Maier D, Alsoufiev AL, Triantafillou AN, Goodnough LT, Santoro SA, et al. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg 1995; 59: 106-111.
20. Boldt J, Schindler E, Osmer C, Wittstock M, Stertmann WA, Hempelmann G. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994; 73: 639-644.
21. Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990; 99: 518-527.
22. Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393-401.
23. Despotis GJ, Filos KS, Zoys TN, Hogue CWJ, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13-21.
24. Jobes DR, Schaffer GW, Aitken GL. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 36-45.
25. Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Kater K, Goodnough LT, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 46-54.
26. Vertrees RA, Engelman RM, Breyer RH, Johnson J, Auvil J, Rousou JA. Protamine-induced anticoagulation following coronary bypass. Proc Am Acad Cardiovasc Perf 1985; 6: 84-88 (abstract).
27. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1995; 58: 799-805.
28. Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Joiner-Maier D, Santoro SA, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemostas 1996; 76: 902-908.
29. de Swart MAC, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258.
30. Olsson P, Lagergren H, Ex S. The elimination from plasma of intravenous heparin. Acta Medica Scandinavica 1963; 173: 619-630.
31. Estes JW, Poulin PF. Pharmacokinetics of heparin: distribution and elimination. Thrombos Diathes Haemorrh (Stuttg) 1975; 33: 26-37.
32. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pbarmacol Ther 1982; 31: 104-113.
33. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107: 271-279.
34. Babson SR, Babson AL. Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations. Am J Clin Pathol 1978; 70: 406-408.
35. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416.
36. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass [review]. Blood 1990; 76: 1680-1697.
37. Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992; 104: 94-107.
38. Valeri CR, Khabbaz K, Khuri SF, Marquardt C, Ragno G, Feingold H, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 1992; 104: 108-116.
39. Valeri CR, Feingold H, Cassidy G, Ragno G, Khuri S, Altschule MD. Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987; 205: 175-181.
40. Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994; 71: 633-640.
41. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-3357.
42. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 828-833.
43. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995; 59: 901-907.
44. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59: 62-67.
45. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989; 3: 181-188.
46. Stibbe J, Kluft C, Brommer EJ, Gomes M, de Jong DS, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-382.
47. Gram J, Janetzko T, Jespersen J, Bruhn HD. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. Thromb Haemost 1990; 63: 241-245.
48. Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-330.
49. Plotz FB, van Oeveren W, Bartlett RH, Wildevuur CR. Blood activation during neonatal extracorporeal life support. J Thorac Cardiovasc Surg 1993; 105: 823-832.
50. Czer LS. Mediastinal bleeding after cardiac surgery: etiologies, diagnostic considerations, and blood conservation methods [review]. J Cardiothorac Anesth 1989; 3: 760-775.
51. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986; 314: 1446-1448.
52. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.
53. Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspurner H, Wolner, E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379-388.
54. John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993; 105: 816-822.
55. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793.
56. Suzuki K, Nishioka J, Hashimoto S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism. Biochim Biophys Acta 1979; 585: 416-426.
57. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 1008-1014.
58. Ereth MH, Klindworth JT, Campbell BA, Sill JC. Protamine attenuates agonist induced platelet signaling/adhesion molecule expression. Anesth Analg 1996; 82: 5 (abstract).
59. Lane DA. Heparin binding and neutralization proteins. In: Lane D, Lindahl U, eds. Heparin: Chemical and Biological Properties. Clinical Application. Boca Raton: CRC Press, 1989; 362.
60. Teoh KH, Young E, Bradley CA, Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation 1993; 88: 420-425.
61. Wu HF, Lundblad RL, Church FC. Neutralization of heparin activity by neutrophil lactoferrin. Blood 1995; 85: 421-428.
62. Anderson EF. Heparin resistance prior to cardiopulmonary bypass. Anesthesiology 1986; 64: 504-507.
63. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer, FC. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983; 85: 346-353.
64. Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas DG. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin concentrations. Ann Thorac Surg 1996; 61: 795-799.
65. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984; 63: 394-398.
66. Milam JD. Blood transfusion in heart surgery. Clin Lab Med 1982; 2: 65-85.
67. Edmunds LH Jr, Ellison N, Colman RW, Niewiarowski S, Rao AK, Addonizio VP Jr, et al. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982; 83: 805-812.
68. Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF. Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979; 77: 427-435.
69. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-562.
70. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gragnon L. Measurement of heparin concentration in whole blood with the hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996; 112: 154-161.
71. Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1996; 170: 1122-1144.
72. McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm 1979; 7: 331-354.
73. Despotis GJ, Levine V, Filos KS, Joiner-Maier D, Joist JH. Hemofiltration increases heparin concentration during cardiopulmonary bypass. Anesth Analg 1997; 84: 479-483.